Icecure Medical (NASDAQ: ICCM) reported a 45% year-over-year revenue increase to $1.8 million for the first half of FY26, driven by growth in ProSense systems and disposable probes.

The medical technology company expanded its gross margin to 30% from 28% in the prior-year period, reflecting increased scale and operating leverage despite foreign exchange fluctuations. Management highlighted a synergistic relationship between clinical evidence generation and commercial adoption as key drivers for long-term growth.

Financial Performance

Revenue for the first half of 2026 rose to $1.8 million from $1.25 million in the same period last year. The growth was attributed to higher sales of both ProSense systems and disposable probes, indicating increased utilization across the commercial installed base.

Gross profit increased to $548,000 from $349,000 in H1FY25. The improvement in gross margin would have been more pronounced absent the impact of foreign exchange fluctuations, which partially offset underlying operational improvements.

Operating expenses increased across all categories due to investments in commercial expansion and clinical programs. Research and development expenses were $4.3 million, up from $3.4 million, primarily driven by the initiation of the Choice Study and foreign exchange impacts on Israel-based costs. Sales and marketing expenses rose to $2.5 million from $2 million, reflecting additional sales hires in key U.S. regions. General and administrative expenses increased to $2.4 million from $1.9 million, influenced by foreign exchange fluctuations on payroll and higher share-based compensation.

The company reported a net loss of $8.8 million ($0.17 per share) for H1FY26, compared to a net loss of $7 million ($0.59 per share) in H1FY25. Icecure ended the period with approximately $12 million in cash and cash equivalents, bolstered by approximately $8.5 million in gross proceeds raised during the second quarter.

What the Numbers Show

While top-line revenue grew by 45%, operating expenses expanded at a faster rate, with R&D up roughly 26% and S&M up 25%. This divergence highlights the capital-intensive nature of the current growth phase, where significant investment in clinical trials (Choice Study) and commercial infrastructure is prioritized over immediate profitability. The net loss widened despite margin expansion, indicating that operational leverage has not yet fully offset the fixed cost base and new strategic expenditures.

Commercial and Clinical Updates

Icecure achieved approximately 70% growth in its active U.S. commercial installed base, now comprising over 30 sites. The company emphasized that increasing disposable probe utilization suggests physicians are incorporating ProSense into routine clinical practice.

Key developments include:

• FDA clearance for early-stage, low-risk breast cancer treatment.
• Positive five-year results from a kidney cancer study presented at ECIO 2026.
• Progress in the Choice post-market study, with expectations to enroll the first patients within three to four weeks.
• Continued engagement with leading physicians and medical societies in Japan for long-term commercialization efforts.

Management stated that the Choice Study serves as an extension of the commercialization strategy, where participating sites purchase disposable probes for routine patient care while contributing real-world clinical evidence.

IceCure Medical Ltd. (NASDAQ: ICCM) has entered into an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands. The deal targets breast cancer and interventional oncology markets.

The agreement positions IceCure to expand commercialization in a market where the independent THERMAC clinical trial is advancing to Phase III. The trial previously identified cryoablation as having the highest complete ablation rate among evaluated thermal technologies.

Strategic Market Entry

Scovas Medical will serve as the exclusive distributor for an initial term, with provisions to negotiate a longer-term arrangement. IceCure cites the Netherlands’ strong interventional radiology expertise and growing interest in minimally invasive procedures as key drivers for the partnership. The Company believes that entering into the initial Agreement with Scovas supports market development, clinical education, and physician access in a country with strong interventional radiology expertise and a growing interest in minimally invasive procedures that support de-escalation of cancer care.

Eyal Shamir, Chief Executive Officer of IceCure Medical, stated that the agreement strengthens the company’s European commercialization strategy. He noted that minimally invasive cryoablation may reduce surgical burden while supporting improved cosmetic outcomes and patient quality of life for selected breast cancer patients.

Clinical Context and Trial Data

The Netherlands is strategically relevant due to the multicenter randomized THERMAC trial conducted there. The trial evaluated thermal ablation as a treatment de-escalation approach for early-stage breast cancer. Investigators selected cryoablation for Phase III based on previously published data indicating superior performance metrics compared to other thermal techniques.

The source states that ProSense® achieved these results without the need for general anesthesia. The high patient satisfaction and zero complication rate contributed to the decision to focus the Phase III trial on cryoablation.

What the Numbers Show

The clinical data presented highlights a divergence between efficacy and safety profiles. A 94% complete ablation rate combined with a 0% complication rate suggests a favorable risk-reward ratio for early-stage breast cancer patients seeking alternatives to surgery. This profile supports IceCure’s positioning of cryoablation as a de-escalation option that maintains oncological control while minimizing procedural burden.

Company Profiles

IceCure Medical develops liquid-nitrogen-based cryoablation therapy systems for benign and cancerous tumors, focusing on breast, kidney, bone, and lung cancer. Its flagship ProSense® system is marketed in the U.S., Europe, and Asia.

Scovas Medical is an independent medical device distributor based in the Netherlands. It provides distribution and clinical sales support across specialties including interventional radiology, vascular surgery, and neurointerventional radiology.